Compare Expedia Group Inc (EXPE) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance

Expedia Group (EXPE) trades at $270.13, up 3.95% today, with strong earnings beats in recent quarters but facing technical bearish signals. The company shows robust fundamentals with 2025 revenue of $14.73B, net income of $1.29B, and healthy cash flow generation. Recent news highlights competitive threats from AI travel agents and workforce reductions, while analyst consensus remains mixed with a $335.06 price target.

EXPE presents a valuation opportunity with P/E of 16.28 below sector averages, but faces significant headwinds from AI disruption in travel booking. The stock's 199% ROE and consistent earnings outperformance support long-term growth potential, though near-term technical weakness and competitive pressures require careful monitoring.

Regeneron Pharmaceuticals (REGN) trades at $739.57, up 0.12% on the day, with a bearish technical signal but strong fundamental performance. Recent earnings have consistently beaten estimates, and the company maintains robust profitability with a net income margin of 27.86%. A major $8 billion expansion of the immunology alliance with Sanofi, announced October 1, 2026, provides significant future revenue potential and strategic momentum.

The outlook is positive, supported by strong earnings, a lucrative partnership, and a consensus analyst price target of $846. Key risks include competitive pressures in key drug markets and reliance on successful clinical trial outcomes. The stock presents a compelling opportunity for growth investors, though volatility may persist near-term.